William Blair analyst Tim Lugo reiterated a Buy rating on Vital Therapies (NASDAQ: VTL) on August 10. The company’s shares closed on Friday at $9.40, close to its 52-week high of $9.75.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 20.3% and a 43.7% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sarepta Therapeutics, and BioMarin.
Currently, the analyst consensus on Vital Therapies is a Moderate Buy with an average price target of $9.
See today’s analyst top recommended stocks >>
Based on Vital Therapies’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $12.68 million. In comparison, last year the company had a GAAP net loss of $12.41 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vital Therapies, Inc. operates as a biotherapeutic company, which develops a human hepatic cell-based system for the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal.
